Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655789 | 0.87 | F10 (0.51) | NPC1RAB9AKDM4EALOX15TSHR | |
| SCHEMBL2657772 | 0.84 | POLB (0.53) | NPC1RAB9AKDM4EGAAALOX15 | |
| SCHEMBL2655767 | 0.83 | SORT1 (0.48) | NPC1RAB9AKDM4EGAAHPGD | |
| SCHEMBL2656637 | 0.81 | GAA (0.47) | GAASMN1; SMN2NTRK1 | |
| SCHEMBL2642895 | 0.80 | KCNMA1 (0.57) | KCNMA1NPC1RAB9AFFAR2KDM4E | |
| SCHEMBL2656303 | 0.77 | FFAR2 (0.47) | FFAR2ALOX15NTRK1 | |
| SCHEMBL2656948 | 0.77 | FFAR2 (0.47) | NPC1RAB9AFFAR2KDM4ESMN1; SMN2 | |
| SCHEMBL2657764 | 0.76 | FFAR2 (0.45) | NPC1RAB9AFFAR2SMN1; SMN2NTRK1 | |
| SCHEMBL2656288 | 0.75 | FFAR2 (0.47) | NPC1RAB9AFFAR2KDM4EGAA | |
| SCHEMBL2655525 | 0.74 | GCK (0.58) | NPC1RAB9AFFAR2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881844-B2 | Indole-3-carboxamides as glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-04-19 | — | — | US | claimed |
| US-20040067939-A1 | Indole-3-carboxamides as glucokinase activators | CORBETT WENDY LEA (US) | 2004-04-08 | — | — | US | claimed |
| US-8148413-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148413-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1549638-B1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | EP | disclosed |
| EP-1549638-B1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | EP | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| EP-1549638-A1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
| US-6881844-B2 | Indole-3-carboxamides as glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-04-19 | — | — | US | disclosed |
| WO-2004031179-A1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031179-A1 | INDOLE-3-CARBOXAMIDES AS GLUCOKINASE (GK) ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| US-20040067939-A1 | Indole-3-carboxamides as glucokinase activators | CORBETT WENDY LEA (US) | 2004-04-08 | — | — | US | disclosed |
| US-20040067939-A1 | Indole-3-carboxamides as glucokinase activators | CORBETT WENDY LEA (US) | 2004-04-08 | — | — | US | disclosed |
| US-20040067939-A1 | Indole-3-carboxamides as glucokinase activators | CORBETT WENDY LEA (US) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067939-A1 | Indole-3-carboxamides as glucokinase activators | GCKR, GPR119, GCK | KCNMA1 737/4885NPC1 4420/4885RAB9A 3647/4885 |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | KCNMA1 1030/4885NPC1 4060/4885RAB9A 4493/4885 |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | GCKR, GCK, GALK1 | KCNMA1 1253/4885NPC1 3131/4885RAB9A 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.